The pharmaceutical company has attributed its profit increase to the sales of drugs targeting cancer and heart conditions.
Pre-tax profit rose by 26% to $6.529 billion (€5.602 billion), with total revenue increasing by 9% to $28.045 billion (€24.064 billion), as announced by AstraZeneca in a statement to the London Stock Exchange.
Operating profit climbed by 23% to $7.182 billion (€6.160 billion), while product sales increased by 8% to $26.670 billion (€22.880 billion).
EBITDA (earnings before interest, taxes, depreciation, and amortization) grew by 17% to $9.855 billion (€8.460 billion).
“The strong momentum in revenue growth continued during the first half of the year, and the results from our broad and diverse product portfolio have been excellent,” said the pharmaceutical company’s CEO, Pascal Soriot.
“As we enter our next phase of growth, we are committed to investing $50 billion to continue expanding in the U.S., including the largest manufacturing investment in AstraZeneca’s history, planned for Virginia,” he added.
According to Soriot, the company is also aiming to achieve $80 billion in revenue by 2030.
